

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	08/965,356
Filing Date	November 6, 1997
First Named Inventor	Merton Bernfield
Group Art Unit	1632
Examiner Name	
Attorney Docket Number	CMCC 533

Sheet	1	of	6
-------	---	----	---

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner's Signature	Anne-Marie Baker	Date Considered	9/29/98
-------------------------	------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	08/965,356
Filing Date	November 6, 1997
First Named Inventor	Merton Bernfield
Group Art Unit	1632
Examiner Name	
Attorney Docket Number	CMCC 533

Sheet 2 of 6

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
AMB		AGRAWAL, et al., "Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus," <i>Proc. Natl. Acad. Sci. USA</i> 85(19):7079-7083 (1988).	
AMB		ASKEW, et al., "Molecular Recognition with Convergent Functional Groups. 6. Synthetic and Structural Studies with a Model Receptor for Nucleic Acid Components," <i>J. Am. Chem. Soc.</i> 111(3):1082-1090 (1989).	
AMB		BERNFELD, et al., "Biology of the Syndecans: A Family of Transmembrane Heparan Sulfate Proteoglycans," in <i>Annu. Rev. Cell Biol.</i> , (Palade, et al., eds.) 8:365-393 (Annual Reviews Inc., Palo Alto, CA, 1992).	
		CLACKSON, et al., "Making antibody fragments using phage display libraries," <i>Nature</i> 352(6336):624-688 (1991).	
		COLDITZ, "Economic costs of obesity," <i>Am. J. Clin. Nutr.</i> 55(2):503S-507S (1992).	
		DAUGHERTY, et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," <i>Nucl. Acids Res.</i> 19(9):2471-2476 (1991).	
		DAVID, et al., "Molecular Cloning of a Phosphatidylinositol-anchored Membrane Heparan Sulfate Proteoglycan from Human Lung Fibroblasts," <i>J. Cell Biol.</i> 111(6):3165-3176 (1990).	
		DAVID, "Integral membrane heparan sulfate proteoglycans," <i>FASEB J.</i> , 7(11):1023-1030 (1993).	
AMB		ELENIUS, et al., "Induced Expression of Syndecan in Healing Wounds," <i>J. Cell Biol.</i> 114(3):585-595 (1991).	
AMB		ELLINGTON, et al., "Selection <i>in vitro</i> of single-stranded DNA molecules that fold into specific ligand-binding structures," <i>Nature</i> 355(6363):850-852 (1992).	
AMB		EZZELL, "Fat Times for Obesity Research: Tons of New Information, but How Does It All Fit Together," <i>J. NIH Res.</i> 7:39-43 (1995).	

Examiner's Signature	Anne Marie Baker	Date Considered	9/29/98
----------------------	------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (10-96
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	08/965,356
Filing Date	November 6, 1997
First Named Inventor	Merton Bernfield
Group Art Unit	1632
Examiner Name	
Attorney Docket Number	CMCC 533

Sheet

3

of

6

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
AMB	•	FLIER, "Commentary - Leptin expression and action: New experimental paradigms," <i>Proc. Natl. Acad. Sci. USA</i> 94(9):4242-4245 (1997).	
AMB		GREENWAY, "Surgery for Obesity," <i>Endo. Metab. Clin. N. Amer.</i> 25(4):1005-1027 (1996).	
AMB		GREGORIADIS, "Liposomes," Chapter 14, <i>Drug Carriers in Biology and Medicine</i> pp. 287-341 (Academic Press, 1979).	
AMB		GUAN, et al., "Fibronectin/integrin interaction induces tyrosine phosphorylation of a 120-kDa protein," <i>Cell Reg.</i> 2(11):951-964 (1991).	
AMB	•	GURA, "Obesity Sheds Its Secrets," <i>Science</i> 275:752-753 (1997).	
		HARADA, et al., "Monoclonal antibody G6K12 specific for membrane-associated differentiation marker of human stratified squamous epithelia and squamous cell carcinoma," <i>J. Oral Pathol. Med.</i> (Denmark), 22(f):145-152 (1993).	
		HAYASHI, et al., "Immunocytochemistry of Cell Surface Heparan Sulfate Proteoglycan in Mouse Tissues. A Light and Electron Microscopic Study," <i>J. Histochem. Cytochem.</i> 35(10):1079-1088 (1987).	
		HIGASHIYAMA, et al., "Heparin-binding EGF-like Growth Factor Stimulation of Smooth Muscle Cell Migration: Dependence on Interactions with Cell Surface Heparan Sulfate," <i>J. Cell Bio.</i> 122(4):933-940 (1993).	
		HUSZAR, et al., "Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice," <i>Cell</i> 88(1):131-141 (1997).	
		INAI, et al., "Immunohistochemical detection of an enamel protein-related epitope in rat bone at an early stage of osteogenesis," <i>Histochemistry</i> (German), 99(5):335-362 (1993).	
AMB		ITAKURA, et al., "Synthesis and Use of Synthetic Oligonucleotides," <i>Ann. Rev. Biochem.</i> 53:323-356 (1984).	

Examiner's Signature	Anne-Marie Baker	Date Considered	9/29/98
-------------------------	------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

⊕ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (10-96
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete If Known

Application Number	08/965,356
Filing Date	November 6, 1997
First Named Inventor	Merton Berfield
Group Art Unit	1632
Examiner Name	
Attorney Docket Number	CMCC 533

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
AMB		JOYNER, et al., "Production of a mutation in mouse <i>En-2</i> gene by homologous recombination in embryonic stem cells," <i>Nature</i> 338(6211):153-156 (1989).	
AMB		KABAT, et al., Sequences of Proteins of Immunological Interest, 4th Ed. (U.S. Dept. Health and Human Services, Bethesda, MD, 1987)	
AMB		LEE, et al., "Change in Body Weight and Longevity," <i>JAMA</i> 268(15):2045-2049 (1992).	
↓		LEWIS, et al., "Automated site-directed drug design: the concept of spacer skeletons for primary structure generation," <i>Proc. R. Soc Lond.</i> 236:125-140 and 141-162 (1989).	
↓		LONG, et al., "Weight Loss in Severely Obese Subjects Prevents the Progression of Impaired Glucose Tolerance to Type II Diabetes," <i>Diabetes Care</i> 17(5):372-375 (1994).	
AMB		McKINALY, et al., "Rational Design of Antiviral Agents," <i>Annu. Rev. Pharmacol. Toxicol.</i> 29:111-122 (1989).	
↓		MERRIFIELD, "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide," <i>J. Am. Chem. Soc.</i> 85:2149-2154 (1964).	
↓		MORTIMER, et al., "Use of Gene-Manipulated Models To Study The Physiology Of Lipid Transport," <i>Clinical and Experimental Pharmacology and Physiology</i> 24(3/4):281-285 (1997).	
↓		MULDER, et al., "Characterization of Two Human Monoclonal Antibodies Reactive with HLA-B12 and HLA-B60, Respectively, Raised by <i>in vitro</i> Secondary Immunization of Peripheral Blood Lymphocytes," <i>Hum. Immunol.</i> 36(3):186-192 (1993).	
↓		NARANG, et al., "Chemical Synthesis of Deoxyligonucleotides by the Modified Triester Method," <i>Methods Enzymol.</i> 65:610-620 (1980).	
AMB		NATIONAL TASK FORCE ON OBESITY, "Long-term Pharmacotherapy in the Management of Obesity," <i>JAMA</i> 276(23):1907-1915 (1996).	

Examiner's Signature	Anne-Marie Baker	Date Considered	9/29/98
-------------------------	------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	08/965,356
Filing Date	November 6, 1997
First Named Inventor	Merton Bernfield
Group Art Unit	1632
Examiner Name	
Attorney Docket Number	CMCC 533

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
AMB		NIH Conference, "Gastrointestinal Surgery for Severe Obesity," <i>Ann Intern Med.</i> 115(12):956-961 (1991).	
		NIH Technology Assessment Conference Panel, "Methods for Voluntary Weight Loss and Control," <i>Ann. Intern. Med.</i> 119(7):764-770 (1993).	
		OFFENSBERGER, et al., "In Vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides," <i>EMBO J.</i> 12(3):1257-1262 (1993).	
		ORSON, et al., "Oligonucleotide inhibition of IL2R α mRNA transcription by promoter region collinear triplex formation in lymphocytes," <i>Nucleic Acids Res.</i> 19(12):3435-3441 (1991).	
AMB		PAULSON, et al., "Glycosyltransferases," <i>J. Biol. Chem.</i> 264(30):17615-17618 (1989).	
		PERRY, et al., <u>QSAR: Quantitative Structure-Activity Relationships in Drug Design</u> (Fauchère, ed.), pp. 189-193 (Alan R. Liss, inc. 1989).	
		POTTER, et al., "Enhancer-dependent expression of human immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation," <i>Proc. Natl. Acad. Sci. USA</i> 81(22):7161-7165 (1984).	
		RAPRAEGER, "The coordinated regulation of heparan sulfate, syndecans and cell behavior," <i>Curr. Opin. Cell Biol.</i> 5(5):844-853 (1993).	
		RAPRAEGER, et al., "Requirement of Heparan Sulfate for bFGF-Mediated Fibroblast Growth and Myoblast Differentiation," <i>Science</i> 252:1705-1708 (1991).	
		RIPKA, "Computers Picture the Perfect Drug," <i>New Scientist</i> 1617:54-57 (1988).	
AMB		ROUVINEN, et al., "Computer-Aided Drug Design," <i>Acta Pharmaceutica Fennica</i> 97:159-166 (1988).	

Examiner's Signature	Anne-Marie Baker	Date Considered	9/29/98
-------------------------	------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	08/965,356
Filing Date	November 6, 1997
First Named Inventor	Merton Bernfield
Group Art Unit	1632
Examiner Name	
Attorney Docket Number	CMCC 533

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
AMB		RUOSLAHTI, et al., "Proteoglycans as Modulators of Growth Factor Activities," <i>Cell</i> 64(5):867-869 (1991).	
		SARIN, et al., "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates," <i>Proc. Natl. Acad. Sci. USA</i> 85(20):7448-7794 (1989).	
		SHAW, et al., "Modified deoxyoligonucleotides stable to exonuclease degradation in serum," <i>Nucleic Acids Res.</i> 19(4):747-750 (1991).	
		SOUTHERN, et al., "Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter," <i>J. Mol. Appl. Gen.</i> 1(4):327-341 (1982).	
		STAUBER, et al., "Rapid generation of monoclonal antibody-secreting hybridomas against African horse sickness virus by <i>in vitro</i> immunization and the fusion/cloning technique," <i>J. Immunol. Methods</i> (Netherlands), 161(2):157-168 (1993).	
		VENKATESWARAN, et al., "Production of Anti-Fibroblast Growth Factor Receptor Monoclonal Antibodies by <i>In Vitro</i> Immunization," <i>Hybridoma</i> 11(6):729-739 (1992).	
AMB		WOLF, et al., "The Cost of Obesity," <i>Pharmacoeconomics</i> 5(Supp. 1):34-37 (1994).	
		WOODS, et al., "A Synthetic Peptide from the COOH-Terminal Heparin-binding Domain of Fibronectin Promotes Focal Adhesion Formation," <i>Molec. Biol. Cell</i> 4(6):605-613 (1993).	
		YAYON, et al., "Cell Surface, Heparin-like Molecules Are Required for Binding of Basic Fibroblast Growth Factor to Its High Affinity Receptor," <i>Cell</i> 64(4):841-848 (1991).	
AMB		ZIMMER, et al., "Production of chimaeric mice containing embryonic stem (ES) cells carrying a homoeobox Hox 1.1 allele mutated by homologous recombination," <i>Nature</i> 338(6211):150-153 (1989).	

Examiner's Signature	Anne-Marie Baker	Date Considered	9/29/98
-------------------------	------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.